Altimmune Q2 net loss $16.1M; pemvidutide obesity trial data expected Q4 2023

Altimmune, Inc.

2023-Q2 EPS reported -$0.72 revenue$27,000

Net loss of $16.1M ($0.32/share) vs $20.1M ($0.42/share) in Q2 2022.
Cash, equivalents & short-term investments totaled $160.0M as of June 30, 2023.
R&D expenses $13.3M, G&A $4.8M for the quarter.
Top-line 48-week MOMENTUM Phase 2 obesity trial results expected Q4 2023.
Enrollment commenced in IMPACT Phase 2b NASH trial; top-line data expected Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Altimmune, Inc. reported the three months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share, EPS $0.32 net loss per share.

Period: the three months ended June 30, 2023
Net income: Net loss for the three months ended June 30, 2023 was $16.1 million, or $0.32 net loss per share
EPS: $0.32 net loss per share
Result: reported results

Exact text from the filing

Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.